Loading organizations...
§ Private Profile · Bangalore, India
Develops at-home hormone trackers, providing precise fertility hormone data via smartphone with AI explanations for women's health and fertility.
Inito has raised $35.0M across 2 funding rounds.
Key people at Inito.
Inito was founded in 2015 by Aayush Rai (Founder) and Varun AV (Founder).
Inito has raised $35.0M in total across 2 funding rounds.
Inito, based in Bengaluru, Karnataka, India, develops at-home hormone trackers, initially focusing on the Inito Fertility Monitor, to simplify healthcare and wellness by providing precise fertility hormone data via smartphone in minutes. The device measures four key fertility hormones, personalizes results with AI explanations, and identifies fertile windows, empowering its over 20,000 users with accurate body insights for conception planning and self-care, independent of traditional healthcare systems. After six years of R&D, patents, and medical publications, the platform has tracked thousands of confirmed pregnancies. An alum of Y Combinator, Inito employs approximately 100 individuals and recently secured $6 million in Series A funding in November 2023, with Fireside Ventures leading the round. The company was founded in 2015 by Aayush Rai and Varun A Venkatesan.
Inito has raised $35.0M across 2 funding rounds. Most recently, it raised $28.9M Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 11, 2025 | $28.9M Series B | — | Kannan Sitaram | Announced |
| Nov 15, 2023 | $6M Series A | Manoj Kumar, Kannan Sitaram | — | Announced |
Key people at Inito.
Inito was founded in 2015 by Aayush Rai (Founder) and Varun AV (Founder).
Inito has raised $35.0M in total across 2 funding rounds.
Inito's investors include Kannan Sitaram, Manoj Kumar.
Inito is a Bengaluru-based startup that develops an at-home fertility hormone tracking device and app designed to empower women with personalized insights into their reproductive health. Its core product is a fertility monitor that measures four key hormones—Estrogen, Luteinizing Hormone (LH), PdG (a progesterone metabolite), and Follicle Stimulating Hormone (FSH)—via urine test strips analyzed through a smartphone-attached device. This approach provides numerical hormone values rather than simple yes/no results, enabling users to identify their full fertile window, confirm ovulation, and manage irregular cycles with greater accuracy. Inito serves women trying to conceive, especially those with irregular menstrual cycles or fertility concerns, by offering a more precise, data-driven alternative to traditional ovulation kits. The company has demonstrated growth momentum, recently raising $6 million in funding and expanding its user base with a product that integrates AI for personalized result interpretation[1][2][4][5].
Inito was founded in 2015 by Aayush Rai (CEO) and Varun A Venkatesan (CTO), both former employees of Siemens’ medtech division. Their shared vision emerged from personal conversations during kayaking sessions, where they expressed a desire to create impactful health technology. They left their corporate roles to build tools that enable better self-care through accessible, precise health monitoring at home. Early traction came from developing a device that combines hardware and software to track multiple fertility hormones simultaneously, a significant innovation over existing single-hormone ovulation tests. This innovation was validated through clinical studies confirming the device’s accuracy and reliability comparable to laboratory tests[1][3][5].
Inito rides the growing trend of personalized digital health and at-home diagnostics, particularly in women’s health—a sector historically underserved by technology. The timing is favorable due to increasing consumer demand for self-care tools, advances in AI for health data interpretation, and a broader shift toward remote health monitoring accelerated by the pandemic. Market forces such as rising fertility awareness, delayed parenthood, and the need for non-invasive, convenient fertility tracking support Inito’s growth. By integrating hardware, software, and AI, Inito influences the fertility-tech ecosystem by setting new standards for precision and user empowerment in reproductive health management[1][5].
Looking ahead, Inito is poised to expand its product capabilities, potentially incorporating more biomarkers and deeper AI-driven analytics to enhance fertility and broader hormonal health insights. Trends such as increasing adoption of digital health tools, rising fertility challenges globally, and growing consumer preference for personalized health data will shape its trajectory. As Inito scales, it may influence the fertility-tech market by pushing competitors toward more comprehensive, data-rich solutions and fostering greater user engagement in reproductive health self-care. Its continued innovation could also open pathways into adjacent women’s health areas, reinforcing its role as a leader in at-home hormone tracking and personalized health technology[1][5].
